Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy

Science Translational Medicine

Volumn 8, Issue 352, 2016, Pages

  Sato, Kazuhide ^a,b   Sato, Noriko ^a   Xu, Biying ^c   Nakamura, Yuko ^a   Nagaya, Tadanobu ^a   Choyke, Peter L ^a   Hasegawa, Yoshinori ^b   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; IFNG PROTEIN, MOUSE; IL2RA PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; CYTOKINE STORM; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NEAR INFRARED PHOTOIMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; PHOTOTHERAPY; PROCEDURES; TRANSLATIONAL RESEARCH; TUMOR CELL LINE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; PHOTOTHERAPY; T-LYMPHOCYTES, REGULATORY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84983565578     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf6843     Document Type: Article

References (43)

1. D. S. Chen, I. Mellman, Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
2. R. W. Childs, M. Carlsten, Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens. Nat. Rev. Drug Discov. 14, 487-498 (2015).
3. C. H. June, S. R. Riddell, T. N. Schumacher, Adoptive cellular therapy: A race to the finish line. Sci. Transl. Med. 7, 280ps7 (2015).
4. I. Melero, D. M. Berman, M. A. Aznar, A. J. Korman, J. L. P. Gracia, J. Haanen, Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).
5. A. M. Lesokhin, M. K. Callahan, M. A. Postow, J. D. Wolchok, On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 7, 280sr1 (2015).
6. P. Sharma, J. P. Allison, The future of immune checkpoint therapy. Science 348, 56-61 (2015).
7. K. M. Mahoney, P. D. Rennert, G. J. Freeman, Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584 (2015).
8. J. F. A. P. Miller, M. Sadelain, The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27, 439-449 (2015).
9. S. L. Topalian, C. G. Drake, D. M. Pardoll, Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
10. L. Zitvogel, L. Galluzzi, M. J. Smyth, G. Kroemer, Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity 39, 74-88 (2013).
11. M. J. Smyth, S. F. Ngiow, A. Ribas, M. W. L. Teng, Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143-158 (2016).
12. G. T. Motz, G. Coukos, Deciphering and reversing tumor immune suppression. Immunity 39, 61-73 (2013).
13. M. S. Goldberg, Immunoengineering: How nanotechnology can enhance cancer immunotherapy. Cell 161, 201-204 (2015).
14. M. Mitsunaga, M. Ogawa, N. Kosaka, L. T. Rosenblum, P. L. Choyke, H. Kobayashi, Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17, 1685-1691 (2011).
15. K. Sato, T. Nakajima, P. L. Choyke, H. Kobayashi, Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv. 5, 25105-25114 (2015).
16. K. Sato, T. Nagaya, Y. Nakamura, T. Harada, P. L. Choyke, H. Kobayashi, Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model. Oncotarget 6, 19747-19758 (2015).
17. K. Sato, T. Nagaya, M. Mitsunaga, P. L. Choyke, H. Kobayashi, Near infrared photoimmunotherapy for lung metastases. Cancer Lett. 365, 112-121 (2015).
18. K. Sato, R. Watanabe, H. Hanaoka, T. Harada, T. Nakajima, I. Kim, C. H. Paik, P. L. Choyke, H. Kobayashi, Photoimmunotherapy: Comparative effectiveness of twomonoclonal antibodies targeting the epidermal growth factor receptor. Mol. Oncol. 8, 620-632 (2014).
19. K. Sato, H. Hanaoka, R. Watanabe, T. Nakajima, P. L. Choyke, H. Kobayashi, Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer. Mol. Cancer Ther. 14, 141-150 (2015).
20. N. Shirasu, H. Yamada, H. Shibaguchi, M. Kuroki, M. Kuroki, Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int. J. Cancer 135, 2697-2710 (2014).
21. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
22. M. P. Colombo, S. Piconese, Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat. Rev. Cancer 7, 880-887 (2007).
23. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
24. A. Facciabene, G. T. Motz, G. Coukos, T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res. 72, 2162-2171 (2012).
25. H. Nishikawa, S. Sakaguchi, Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1-7 (2014).
26. W. Zou, Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
27. + regulatory T cells. J. Exp. Med. 202, 885-891 (2005).
28. + regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. U.S.A. 110, 17945-17950 (2013).
29. S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, E. Nakayama, Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a monoclonal antibody. Cancer Res. 59, 3128-3133 (1999).
30. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201, 779-791 (2005).
31. X. Li, E. Kostareli, J. Suffner, N. Garbi, G. J. Hämmerling, Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol. 40, 3325-3335 (2010).
32. M. W. L. Teng, S. F. Ngiow, B. von Scheidt, N. McLaughlin, T. Sparwasser, M. J. Smyth, Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 70, 7800-7809 (2010).
33. P. D. Bos, G. Plitas, D. Rudra, S. Y. Lee, A. Y. Rudensky, Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 210, 2435-2466 (2013).
34. C. L. Freeman, F. Morschhauser, L. Sehn, M. Dixon, R. Houghton, T. Lamy, G. Fingerle-Rowson, E. Wassner-Fritsch, J. G. Gribben, M. Hallek, G. Salles, G. Cartron, Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood 126, 2646-2649 (2015).
35. S. Ganesh, M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
36. J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, A. Berdelou, A. Varga, R. Bahleda, A. Hollebecque, C. Massard, A. Fuerea, V. Ribrag, A. Gazzah, J. P. Armand, N. Amellal, E. Angevin, N. Noel, C. Boutros, C. Mateus, C. Robert, J. C. Soria, A. Marabelle, O. Lambotte, Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur. J. Cancer 54, 139-148 (2016).
37. M. Nishino, L. M. Sholl, F. S. Hodi, H. Hatabu, N. H. Ramaiya, Anti-PD-1-related pneumonitis during cancer immunotherapy. N. Engl. J. Med. 373, 288-290 (2015).
38. P. Attia, A. V. Maker, L. R. Haworth, L. Rogers-Freezer, S. A. Rosenberg, Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389 IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28, 582-592 (2005).
39. M. W. L. Teng, J. B. Swann, B. von Scheidt, J. Sharkey, N. Zerafa, N. McLaughlin, T. Yamaguchi, S. Sakaguchi, P. K. Darcy, M. J. Smyth, Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res. 70, 2665-2674 (2010).
40. + regulatory T cells following anti-CD25 treatment in malariainfected mice. J. Immunol. 178, 4136-4146 (2007).
41. D. Anz, W. Mueller, M. Golic, W. G. Kunz, M. Rapp, V. H. Koelzer, J. Ellermeier, J. W. Ellwart, M. Schnurr, C. Bourquin, S. Endres, CD103 is a hallmark of tumor-infiltrating regulatory T cells. Int. J. Cancer 129, 2417-2426 (2011).
42. Y.-C. Lin, L.-Y. Chang, C.-T. Huang, H.-M. Peng, A. Dutta, T.-C. Chen, C.-T. Yeh, C.-Y. Lin, Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity. J. Immunol. 182, 6095-6104 (2009).
43. T. Tanaka, M. Narazaki, T. Kishimoto, IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6, a016295 (2014).